Test Price
2,800 AED✅ Home Collection Available
ANTXR1 Gene Hemangioma Capillary Infantile Genetic Test (NGS) in UAE
Executive Summary & Core Metrics
This advanced next-generation sequencing (NGS) genetic test examines the ANTXR1 gene for mutations associated with capillary infantile hemangioma, delivering 99.9% diagnostic sensitivity through ISO-accredited processing. The test is performed at DNA Labs UAE, a DHA-licensed facility (License 1143) in Dubai Healthcare City. Service includes VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM, plus telephonic post-test clinical guidance. For insurance verification and booking, contact us via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ANTXR1 gene sequencing test provides definitive molecular diagnosis for capillary infantile hemangioma, enabling personalized management and family counseling. Using next-generation sequencing, the entire coding region of the ANTXR1 gene is analyzed with high depth to detect pathogenic variants, insertions, deletions, and splice-site alterations.
| Feature | Our Test (NGS) | Standard Genetic Testing |
|---|---|---|
| Precision (Diagnostic Sensitivity) | 99.9% (ISO 9001:2015 Certified) | ~85-90% (single-gene Sanger) |
| Methodology | NGS (Next Generation Sequencing) – full gene coverage | Targeted mutation panel or Sanger sequencing |
| Turnaround Time | 3–4 Weeks | 5–8 Weeks |
| Sample Types | Blood, Extracted DNA, One Drop Blood on FTA Card | Blood only (not FTA card) |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I have guided many families through the diagnosis and management of pediatric vascular anomalies. This NGS-based test for the ANTXR1 gene offers a high-resolution view of the underlying genetics, but results must always be interpreted in the context of the full clinical picture. Do not alter treatment based solely on a genetic result; always consult with your pediatrician or geneticist. We are here to support you with compassionate expertise.”
⚠️ Medication Advisory
Do not discontinue or modify prescribed medication without consulting your doctor.
🚨 Exclusion Criteria & ER Red Flags
- Exclusion Criteria: Patients without clinical indication of hemangioma or a family history of ANTXR1-related syndrome. Minors must have informed consent from parent/legal guardian.
- ER Red Flags: If the child exhibits facial hemangioma with airway compromise, active bleeding, or ulceration with infection, seek emergency medical evaluation immediately. Genetic testing is not a substitute for acute management.
Patient FAQ & Clinical Guidance
1. What is the ANTXR1 gene test for infantile hemangioma?
First answer snippet: The ANTXR1 Genetic Test detects pathogenic mutations in the ANTXR1 gene causing capillary infantile hemangioma with 99.9% sensitivity.
This test uses next-generation sequencing to examine the entire coding region of the ANTXR1 gene, providing a comprehensive risk assessment for both the patient and family members. Early identification of a pathogenic variant can guide multidisciplinary management, including dermatologic, oncologic, and genetic counseling.
2. How long does it take to receive results?
First answer snippet: Your ANTXR1 NGS results are typically ready within 3 to 4 weeks from sample receipt at our laboratory.
The turnaround time considers comprehensive DNA extraction, library preparation, high-depth sequencing, and rigorous bioinformatics analysis, ensuring the highest diagnostic accuracy. You will be notified via WhatsApp once the report is finalized.
3. Is home collection available and safe for infants?
First answer snippet: Yes, our VIP mobile phlebotomy service offers hospital-grade home collection for infants with certified cold-chain transport, ensuring sample integrity.
All samples are collected by DHA-licensed pediatric phlebotomists using minimally invasive techniques, in compliance with UAE regulations for minors. The collected sample is immediately stored in ISO-certified coolers and transported to our facility within 2 hours.
UAE Regulatory & Data Privacy Adherence
Legal & Compliance: This medical service adheres to the UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory operates under DHA Facility License No. 1143 and is ISO 9001:2015 certified.
Clinical & Logistical Metadata
| Test Name | ANTXR1 Gene Hemangioma Capillary Infantile Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood, extracted DNA, or FTA card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM–11 PM) |
| Methodology Used | Next Generation Sequencing (NGS) – full gene coverage |
| ICD-10-CM Code | Q82.8 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians